|
Market Closed -
Other stock markets
|
After hours 05:28:21 am | |||
| 115.09 USD | +0.18% |
|
115.22 | +0.12% |
| 15/07 | BofA Securities Raises Incyte Price Target to $136 From $124 | MT |
| 14/07 | Barclays Adjusts Incyte Price Target to $134 From $117, Maintains Overweight Rating | MT |
Insider Transaction History
Latest insider transactions for Incyte Corporation
| Date | Insider | Type | Main position | Quantity | Price | Amount | % Market Cap. | |
|---|---|---|---|---|---|---|---|---|
| 02/07 | Tax | Principal Accounting Officer | -477 | 116.86 | - | 0.0002% | ||
| 02/07 | Tax | Chief Technology Officer | -2,177 | 116.86 | - | 0.0011% | ||
| 02/07 | Tax | EVP & Chief Scientific Officer | -350 | 116.86 | - | 0.0002% | ||
| 02/07 | Tax | Chief Executive Officer | -4,779 | 116.86 | - | 0.0024% | ||
| 30/06 | FBS Associates LLC
| Other | Company | 0 | 116.86 | - | 0% | |
| 30/06 | Other | Director | 0 | 116.86 | - | 0% | ||
| 30/06 | Baker Bros. Advisors LP
| Free | Company | 800 | - | - | 0.0004% | |
| 30/06 | Other | Chairman | 0 | 116.86 | - | 0% | ||
| 30/06 | Free | Director | 255 | 113.36 | 28.91T | 0.0001% | ||
| 30/06 | Free | Director | 252 | 113.36 | 28.57T | 0.0001% | ||
| 08/06 | Free | Director | 7,753 | - | - | 0.0039% | ||
| 08/06 | FBS Associates LLC
| Other | Company | 0 | 107.83 | - | 0% | |
| 08/06 | Baker Bros. Advisors LP
| Free | Company | 15,506 | - | - | 0.0078% | |
| 08/06 | Other | Chairman | 0 | 107.83 | - | 0% | ||
| 08/06 | Free | Director | 7,753 | - | - | 0.0039% | ||
| 08/06 | Other | Director | 0 | 107.83 | - | 0% | ||
| 08/06 | Free | Director | 7,753 | - | - | 0.0039% | ||
| 08/06 | Free | Director | 7,753 | - | - | 0.0039% | ||
| 08/06 | Free | Director | 7,753 | - | - | 0.0039% | ||
| 08/06 | Free | Director | 7,753 | - | - | 0.0039% | ||
| 04/06 | Fiscal year | Principal Accounting Officer | 7,917 | 91.92 | 5L | 0.0040% | ||
| 01/06 | Tax | Chairperson | -25,469 | 95.59 | - | 0.0127% | ||
| 26/05 | Sell | Principal Accounting Officer | -2,051 | 97.35 | - | 0.0010% | ||
| 26/05 | Fiscal year | Director | 43,059 | 90.38 | 25.36L | 0.0216% | ||
| 19/05 | Fiscal year | Director | 45,000 | 89.73 | 26.92L | 0.0226% | ||
| 08/05 | Other | Director | 0 | 99.13 | - | 0% | ||
| 08/05 | FBS Associates LLC
| Other | Company | 0 | 99.13 | - | 0% | |
| 08/05 | Other | Chairman | 0 | 99.13 | - | 0% | ||
| 08/05 | Baker Bros. Advisors LP
| Fiscal year | Company | 60,000 | 84.53 | 25.36L | 0.0301% | |
| 06/05 | Free | Chairperson | 31,517 | - | - | 0.0158% | ||
| 06/05 | Free | Chief Technology Officer | 44,124 | - | - | 0.0222% | ||
| 04/05 | Free | Chief Financial Officer | 77,943 | - | - | 0.0392% | ||
| 17/04 | Fiscal year | Chairperson | 56,001 | 82.96 | 30.97L | 0.0281% | ||
| 15/04 | Fiscal year | Chief Executive Officer | 1,25,000 | - | - | 0.0628% | ||
| 31/03 | Other | Chairman | 0 | - | - | 0% | ||
| 31/03 | Baker Bros. Advisors LP
| Free | Company | 842 | - | - | 0.0004% | |
| 31/03 | Other | Director | 0 | - | - | 0% | ||
| 31/03 | FBS Associates LLC
| Other | Company | 0 | - | - | 0% | |
| 31/03 | Free | Director | 269 | 94.12 | 25.32T | 0.0001% | ||
| 31/03 | Free | Director | 265 | 94.12 | 24.94T | 0.0001% | ||
| 25/03 | Tax | EVP, GM, Dermatology US | 537 | 92.23 | 49.53T | 0.0003% | ||
| 17/03 | Fiscal year | Chairperson | 56,001 | 78.66 | 29.37L | 0.0281% | ||
| 19/02 | Fiscal year | Chairperson | 56,004 | 81.25 | 30.33L | 0.0285% | ||
| 02/02 | Tax | EVP, Head of Incyte Intl | 111 | 102.67 | 11.4T | 0.0001% | ||
| 02/02 | Tax | Chief Technology Officer | 185 | 102.67 | 18.99T | 0.0001% | ||
| 16/01 | Free | Chief Technology Officer | 19,932 | - | - | 0.0102% | ||
| 16/01 | Free | Chairperson | 28,475 | - | - | 0.0145% | ||
| 16/01 | Free | EVP, Head of US Oncology | 14,237 | - | - | 0.0073% | ||
| 16/01 | Free | EVP & Chief Scientific Officer | 4,218 | - | - | 0.0021% | ||
| 16/01 | Free | EVP, Head of Incyte Intl | 8,911 | - | - | 0.0045% | ||
- Stock Market
- Stocks
- INCY Stock
- Company Incyte Corporation
- Insider transactions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















